EUVIMEDEUVIMED entdecken
Crossref

Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer

Meshael Alswailem, Balgees Alghamdi, Anwar Alotaibi, Abeer Aljomiah, Hindi Al-Hindi, Avaniyapuram Kannan Murugan, Mohamed Abouelhoda, Yufei Shi iD, Ali S Alzahrani iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Meshael Alswailem und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: King Faisal Specialist Hospital and Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Diffuse sclerosing papillary thyroid cancer (DSPTC) is rare, with limited data on its molecular genetics.

Objective

We studied the molecular genetics of a cohort of DSPTC.

Methods

DNA was isolated from paraffin blocks of 22 patients with DSPTC (15 females, 7 males, median age 18 years, range 8-81). We performed polymerase chain reaction–based Sanger sequencing and a next-generation sequencing (NGS) gene panel to characterize the genomic landscape of these tumors. We classified genetic alterations to definitely or probably pathogenic. Definitely pathogenic are genetic alterations that are well known to be associated with PTC (e.g., BRAFV600E). Probably pathogenic are other alterations in genes that were reported in The Cancer Genome Atlas or the poorly differentiated and anaplastic thyroid cancer datasets.

Results

Three tumors were tested only by Sanger sequencing and were negative for BRAFV600E, HRAS, KRAS, NRAS, TERT promoter, PTEN, and PIK3CA mutations. The other 19 tumors tested by NGS showed definitely pathogenic alterations in 10 patients (52.6%): 2/19 (10.5%) BRAFV600E, 5/19 (26.3%) CCDC6-RET (RET/PTC1), 1/19 (5.3%) NCOA4-RET (RET/PTC3), 1/19 (5.3%) STRN-ALK fusion, and 2/19 (10.6%) TP53 mutations. Probably pathogenic alterations occurred in 13/19 tumors (68.4%) and included variants in POLE (31.6%), CDKN2A (26%), NF1 (21%), BRCA2 (15.8%), SETD2 (5.3%), ATM (5.3%), FLT3 (5.3%), and ROS1 (5.3%). In 1 patient, the gene panel showed no alterations. No mutations were found in the RAS, PTEN, PIK3CA, or TERT promoter in all patients. There was no clear genotype/phenotype correlation.

Conclusion

In DSPTC, fusion genes are common, BRAFV600E is rare, and other usual point mutations are absent. Pathogenic and likely pathogenic variants in POLE, NF1, CDKN2A, BRCA2, TP53, SETD2, ATM, FLT3, and ROS1 occur in about two-thirds of DTPTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsMaleFemaleHumansThyroid Cancer, PapillaryProtein-Tyrosine KinasesProto-Oncogene ProteinsMolecular BiologyProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

diffuse sclerosing papillary thyroid cancerfusion genesgene panelmutationspapillary thyroid cancer

Substanzen

Protein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Molecular Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
  • Department of Biostatistics, Epidemiology & Scientific Computing, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
  • Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
  • Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
  • Center for Genomic Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.

ORCID-Profile: Yufei Shi, Ali S Alzahrani

Förderung

  • King Faisal Specialist Hospital and Research Centre

Zitieren

APA

Alswailem, M., Alghamdi, B., Alotaibi, A., Aljomiah, A., Al-Hindi, H., Murugan, A. K., Abouelhoda, M., Shi, Y., & Alzahrani, A. S. (2023). Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad185

Vancouver

Alswailem M, Alghamdi B, Alotaibi A, Aljomiah A, Al-Hindi H, Murugan AK, et al. Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad185

BibTeX
@article{Alswailem2023,
  author = {Alswailem, Meshael and Alghamdi, Balgees and Alotaibi, Anwar and Aljomiah, Abeer and Al-Hindi, Hindi and Murugan, Avaniyapuram Kannan and Abouelhoda, Mohamed and Shi, Yufei and Alzahrani, Ali S},
  title = {Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad185}
}
Kostenlos starten →